An umbrella review of the prevalence of depression during the COVID-19 pandemic: Call to action for post-COVID-19 at the global level.

Publication date: Dec 23, 2024

Pandemics can lead to mental health problems such as depression. This meta-analysis of meta-analyses aimed to estimate the precise prevalence of depression during the COVID-19 pandemic. Web of Science, PubMed, Scopus, and Embase were searched for published meta-analyses using relevant keywords, such as depression, prevalence, COVID-19, and meta-analysis up to March 18, 2024 according to the PRISMA guidelines. Relevant journals as well as the search engine Google Scholar were manually searched to discover more articles. The AMSTAR tool was used for quality assessment. A random-effects model was used for the analysis. All analyses were conducted using the STATA 17 software. Of 535 records, 82 meta-analyses were included. The results showed that the overall prevalence of depression was 30% [95% CI: 29-32] with a high heterogeneity (I: 90. 98%). The highest prevalence of depression according to population group was found in medical students (40% [30-49]), specific groups (40% [3-78]), and patients (36% [27-45]). The results of meta-regression based on the different times between the start of COVID-19 and the last date of search in the articles (week) and the prevalence of depression, showed that each past week of Covid-19 increases the prevalence of depression by almost 0. 00021% [95% CI: -0. 00025, 0. 00068], P-value: 0. 36, but “time” is not a significant predictor of an increase in depression. The results showed that the prevalence of depression was high during the COVID-19 pandemic, particularly among medical students. Policy makers should pay more attention to these groups and those who are at greater risk. Primary mental health interventions and policies are necessary to support the mental health of these individuals during the pandemic.

Open Access PDF

Concepts Keywords
Google COVID-19
Pandemic Depression
Students Meta-analysis
Umbrella Pandemic
Prevalence

Semantics

Type Source Name
disease MESH depression
disease MESH COVID-19 pandemic
disease IDO quality
pathway REACTOME Reproduction
disease MESH infection
disease MESH anxiety
disease MESH suicide
disease MESH chronic diseases
drug DRUGBANK Trestolone
disease MESH Mental disorders
drug DRUGBANK Coenzyme M
drug DRUGBANK Methionine
disease IDO process
drug DRUGBANK Trimebutine
drug DRUGBANK Indoleacetic acid
disease MESH PTSD
disease MESH insomnia
disease MESH anxiety disorder
disease MESH social anxiety disorder
disease MESH panic disorder
disease MESH suicidal ideation
disease MESH major depressive disorder
disease MESH uncertainty
disease MESH death
disease MESH psychological distress
disease MESH hypertension
drug DRUGBANK Etoperidone
drug DRUGBANK Guanosine
disease MESH syndromes
disease MESH morbidities
disease MESH sleep disorders
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Adenosine
disease MESH eating disorder
disease MESH infectious diseases
disease MESH postpartum depression
drug DRUGBANK Silver
drug DRUGBANK Ilex paraguariensis leaf
disease MESH long COVID
disease MESH emergencies
drug DRUGBANK Methyl isocyanate
disease MESH Sleep quality
disease MESH Loneliness
drug DRUGBANK Ketamine
disease MESH treatment resistant depression
disease IDO intervention

Original Article

(Visited 3 times, 1 visits today)